Boston Scientific is snatching up Cosman Medical to get its hands on the company’s radiofrequency ablation (RFA) systems to expand its neuromodulation portfolio.
Neither side is revealing financial details, but Cosman Medical’s team and devices will be wrapped into Boston Scientific’s neuromodulation business as a result of the deal, the company said in a statement. Marlborough, MA-based Boston Scientific’s neuromodulation offerings include spinal cord stimulators (SCS) for patients with chronic pain and deep brain stimulation systems for conditions such as Parkinson’s disease and dystonia.
“This acquisition is a natural extension of our current product portfolio and will help us provide physicians and patients more options to address chronic pain with non-opioid therapeutic treatments,” Maulik Nanavaty, senior vice president and president of Boston Scientific’s neuromodulation business, said in a statement. “The addition of the Cosman Medical product line, which is built on industry-leading technology and known for its high-quality, expands our capability to provide innovative solutions for the treatment of chronic pain.”
The deal comes as physicians look for alternative ways to treat chronic pain. Cosman’s RFA systems apply heat to small areas of nerve tissue to cut off pain signals. The devices are typically used before spinal cord stimulation, which sends electrical signals to the spinal cord to prevent pain signals from reaching the brain.
A deal with Cosman Medical also comes on the heels of change. Boston Scientific recently announced a global restructuring program “to support long-term growth and innovation” after 7 of its businesses posted double-digit organic growth in the first quarter of 2016.
Part of Boston Scientific’s reorganization involves focusing on “developing global commercialization, technology and manufacturing capabilities in key growth markets, continuing implementation of the company’s plant network optimization strategy and expanding operational efficiencies,” the company said last month. Beefing up in neuromodulation could play a key role in its transformation.
By Emily Wasserman
Source: Fierce Biotech
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
